Julphar Invests SAR 300 Million to Establish Integrated Pharmaceutical Facility in Saudi Arabia

Jeddah | EcoPulse24
Gulf Pharmaceutical Industries (Julphar) has signed a long-term lease agreement with the Third Industrial City in Jeddah, paving the way for the establishment of a fully integrated pharmaceutical manufacturing facility in Saudi Arabia. This strategic move aims to localize drug production, bolster health security, and position the Kingdom as a regional export hub for pharmaceutical products.

The project follows Julphar’s earlier announcement of direct industrial investments in the Saudi market, aligning with the objectives of Saudi Vision 2030, particularly in technology transfer, local content enhancement, and supporting self-sufficiency in vital industries.

According to disclosed data, the total investment value is approximately SAR 300 million. The facility will be built on a 45,000-square-meter site and is expected to provide up to 1,400 direct jobs at full operation, supporting economic growth and expanding employment in the pharmaceutical manufacturing sector.

The facility’s location in one of the Kingdom’s key industrial cities ensures efficient supply chains, improved logistics, and easy access to both local and international export markets. The new plant will serve as a pharmaceutical export platform to the US and other global markets, leveraging Julphar’s export experience in over 40 countries worldwide.

Technically, the facility will utilize advanced manufacturing technologies, including sterile injectable products and solid oral dosage forms, with a focus on biologics and specialized medicines for critical care and chronic diseases, adhering to the highest standards of quality, safety, and regulatory compliance.

Sheikh Saqr Bin Humaid Bin Abdullah Al Qasimi, Chairman of Julphar, stated that the project marks a significant milestone in the company’s regional expansion and reflects its commitment to health security, local pharmaceutical manufacturing, and sustainable industrial development in the Kingdom.

Dr. Basel Ziadeh, CEO of Julphar, emphasized that the investment in Saudi Arabia is a long-term commitment that strengthens the company’s position as a leading pharmaceutical manufacturer in the Middle East and North Africa. He noted that the facility will employ the latest production technologies, prioritize national talent development, and build sustainable manufacturing capabilities to meet growing demand in the Saudi and regional markets.